232 related articles for article (PubMed ID: 28387565)
1. The Therapeutic Potential of Piceatannol, a Natural Stilbene, in Metabolic Diseases: A Review.
Kershaw J; Kim KH
J Med Food; 2017 May; 20(5):427-438. PubMed ID: 28387565
[TBL] [Abstract][Full Text] [Related]
2. Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects.
Hijona E; Aguirre L; Pérez-Matute P; Villanueva-Millán MJ; Mosqueda-Solis A; Hasnaoui M; Nepveu F; Senard JM; Bujanda L; Aldámiz-Echevarría L; Llarena M; Andrade F; Perio P; Leboulanger F; Hijona L; Arbones-Mainar JM; Portillo MP; Carpéné C
J Physiol Biochem; 2016 Sep; 72(3):567-82. PubMed ID: 26792656
[TBL] [Abstract][Full Text] [Related]
3. Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.
Les F; Deleruyelle S; Cassagnes LE; Boutin JA; Balogh B; Arbones-Mainar JM; Biron S; Marceau P; Richard D; Nepveu F; Mauriège P; Carpéné C
Chem Biol Interact; 2016 Oct; 258():115-25. PubMed ID: 27475863
[TBL] [Abstract][Full Text] [Related]
4. Exploring the therapeutic potential of naturally occurring piceatannol in non-communicable diseases.
Gandhi H; Mahant S; Sharma AK; Kumar D; Dua K; Chellappan DK; Singh SK; Gupta G; Aljabali AAA; Tambuwala MM; Kapoor DN
Biofactors; 2024; 50(2):232-249. PubMed ID: 37702264
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Review on the Chemotherapeutic Potential of Piceatannol for Cancer Treatment, with Mechanistic Insights.
Seyed MA; Jantan I; Bukhari SN; Vijayaraghavan K
J Agric Food Chem; 2016 Feb; 64(4):725-37. PubMed ID: 26758628
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of piceatannol: leaving the shadow of resveratrol.
Piotrowska H; Kucinska M; Murias M
Mutat Res; 2012; 750(1):60-82. PubMed ID: 22108298
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol in metabolic health: an overview of the current evidence and perspectives.
Poulsen MM; Jørgensen JO; Jessen N; Richelsen B; Pedersen SB
Ann N Y Acad Sci; 2013 Jul; 1290():74-82. PubMed ID: 23855468
[TBL] [Abstract][Full Text] [Related]
8. Nutritional activities of luteolin in obesity and associated metabolic diseases: an eye on adipose tissues.
Zhang Z; Wang J; Lin Y; Chen J; Liu J; Zhang X
Crit Rev Food Sci Nutr; 2024; 64(12):4016-4030. PubMed ID: 36300856
[TBL] [Abstract][Full Text] [Related]
9. A review of the pharmacological effects of piceatannol on cardiovascular diseases.
Tang YL; Chan SW
Phytother Res; 2014 Nov; 28(11):1581-8. PubMed ID: 24919577
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Effect of Piceatannol on TNF-α-Mediated Inflammation and Insulin Resistance in 3T3-L1 Adipocytes.
Li Y; Yang P; Chang Q; Wang J; Liu J; Lv Y; Wang TTY; Gao B; Zhang Y; Yu LL
J Agric Food Chem; 2017 Jun; 65(23):4634-4641. PubMed ID: 28535046
[TBL] [Abstract][Full Text] [Related]
11. Piceatannol Is Superior to Resveratrol at Suppressing Adipogenesis in Human Visceral Adipose-Derived Stem Cells.
Park IS; Han Y; Jo H; Lee KW; Song YS
Plants (Basel); 2021 Feb; 10(2):. PubMed ID: 33672932
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Gymnema sylvestre in High-Fat Diet-Induced Metabolic Disorders.
Kim HJ; Kim S; Lee AY; Jang Y; Davaadamdin O; Hong SH; Kim JS; Cho MH
Am J Chin Med; 2017; 45(4):813-832. PubMed ID: 28514906
[TBL] [Abstract][Full Text] [Related]
13. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats.
Rivera L; Morón R; Zarzuelo A; Galisteo M
Biochem Pharmacol; 2009 Mar; 77(6):1053-63. PubMed ID: 19100718
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice.
Komori T; Tanaka M; Furuta H; Akamizu T; Miyajima A; Morikawa Y
Diabetologia; 2015 Aug; 58(8):1868-76. PubMed ID: 25972231
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress and lipid peroxidation by-products at the crossroad between adipose organ dysregulation and obesity-linked insulin resistance.
Murdolo G; Piroddi M; Luchetti F; Tortoioli C; Canonico B; Zerbinati C; Galli F; Iuliano L
Biochimie; 2013 Mar; 95(3):585-94. PubMed ID: 23274128
[TBL] [Abstract][Full Text] [Related]
16. Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats.
Llarena M; Andrade F; Hasnaoui M; Portillo MP; Pérez-Matute P; Arbones-Mainar JM; Hijona E; Villanueva-Millán MJ; Aguirre L; Carpéné C; Aldámiz-Echevarría L
J Physiol Biochem; 2016 Sep; 72(3):555-66. PubMed ID: 26660756
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential and Molecular Targets of Piceatannol in Chronic Diseases.
Surh YJ; Na HK
Adv Exp Med Biol; 2016; 928():185-211. PubMed ID: 27671818
[TBL] [Abstract][Full Text] [Related]
18. Ageing, adipose tissue, fatty acids and inflammation.
Pararasa C; Bailey CJ; Griffiths HR
Biogerontology; 2015 Apr; 16(2):235-48. PubMed ID: 25367746
[TBL] [Abstract][Full Text] [Related]
19. Piceatannol lowers the blood glucose level in diabetic mice.
Uchida-Maruki H; Inagaki H; Ito R; Kurita I; Sai M; Ito T
Biol Pharm Bull; 2015; 38(4):629-33. PubMed ID: 25832644
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: a key to lean phenotype.
Flachs P; Rossmeisl M; Kuda O; Kopecky J
Biochim Biophys Acta; 2013 May; 1831(5):986-1003. PubMed ID: 23454373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
